Chardan Capital Boosts Ocugen (NASDAQ:OCGN) Price Target to $5.00

Ocugen (NASDAQ:OCGN) had its target price boosted by Chardan Capital from $4.00 to $5.00 in a research note issued to investors on Monday, Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $7.00 target price on shares of Ocugen in a research report on Wednesday, April 3rd.

Ocugen Stock Performance

NASDAQ:OCGN opened at $1.24 on Monday. The company has a current ratio of 2.51, a quick ratio of 2.51 and a debt-to-equity ratio of 0.07. Ocugen has a 12-month low of $0.35 and a 12-month high of $2.11. The stock has a 50-day moving average price of $1.24 and a 200 day moving average price of $0.74. The stock has a market capitalization of $319.09 million, a P/E ratio of -4.59 and a beta of 3.51.

Hedge Funds Weigh In On Ocugen

An institutional investor recently bought a new position in Ocugen stock. David J Yvars Group purchased a new stake in shares of Ocugen, Inc. (NASDAQ:OCGN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 21,170 shares of the company’s stock, valued at approximately $35,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.